On August 4, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported it will participate in a JonesTrading webinar with oncology key opinion leaders (KOLs) and Shaun Bagai, Chief Executive Officer of RenovoRx, on August 13, 2026 at 1:30 p.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar, The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx’s TAMP Platform and Emerging Clinical Advances, will be moderated by Justin Walsh, Equity Research Analyst covering the healthcare sector at JonesTrading. He will be joined by Dae Won Kim, MD, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center, Ravi Shridhar, MD, PhD, Theranostic Program Director in the Department of Radiation Oncology at AdventHealth Cancer Institute, and Mr. Bagai.
Clinical Topics
● The exciting and rapidly evolving pancreatic cancer treatment landscape.
● RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform, enabled by the RenovoCath device, and its potential to deliver various existing and new chemotherapies locally rather than systemically.
● The ongoing Phase III TIGeR-PaC clinical trial, which is evaluating intra-arterial gemcitabine delivered via RenovoCath, as a potential treatment for locally advanced pancreatic cancer.
● Clinical experience integrating TAMP chemotherapy delivery via RenovoCath as a commercially available stand-alone medical device product into medical practice.
RenovoRx Commercial and Financial Topics
● Promising commercial launch of RenovoCath as a stand-alone device within its FDA-cleared uses, with growing revenues and a pathway for continued revenue expansion.
● Increasing the number of active commercial cancer center customers and their utilization of TAMP and RenovoCath to drive revenue and reduce the Company’s cash burn.
Webinar Details:
Title: The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx’s TAMP Platform and Emerging Clinical Advances
Date: Thursday, August 13, 2026
Time: 1:30 p.m. ET
Speakers: Dae Won Kim, MD, Moffitt Cancer Center,
Ravi Shridhar, MD, PhD, AdventHealth Cancer Institute, and
Shaun Bagai, Chief Executive Officer, RenovoRx
Moderator: Justin Walsh, Equity Research Analyst, Healthcare, JonesTrading
Webcast: View Source
For interested individuals unable to join the webinar, a replay of the webcast will be available at View Source.
(Press release, Renovorx, AUG 4, 2026, View Source [SID1234669666])